Oväntad effekt

Active Biotechs läkemedelskandidat laquinimod visar även effekt på depression och ångest.

By Nyhetsbyrån Direkt

March 20, 2013 12:00 AM

STOCKHOLM (Direkt) Läkemedelskandidaten laquinimod, som Active Biotech har utlicensierat till Teva, skulle kunna lindra depression och ångest i samband med MS eller oberoende av MS.

Det framgår av material inför en läkemedelskongress i Kyoto i slutet av juni.

Börsredaktionen +46 8 5191 7910

Nyhetsbyrån Direkt

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.